SCHEMBL2543933

SCHEMBL2543933

Cc1ccc(O)c(Cn2cnc3ccc(CNc4cccc(Cl)c4)cc32)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ EGFR P00533 4/20 0.40
▸ BRD4 O60885 2/20 0.40
▸ SCD O00767 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ GFER P55789 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ GRM5 P41594 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ EP300 Q09472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12226859 0.79 ALDH1A1 (0.47) RAB9ABRD4KCNH2GFERSMN1; SMN2
SCHEMBL12930990 0.74 TNF (0.35) NPC1RAB9AGFERSMN1; SMN2KDM4E
SCHEMBL12226863 0.74 ALDH1A1 (0.39) RAB9ABRD4KCNH2GFERSMN1; SMN2
SCHEMBL12226864 0.73 ALDH1A1 (0.38) RAB9ABRD4KCNH2GFERSMN1; SMN2
SCHEMBL2537168 0.73 MAPT (0.46) NPC1RAB9ASCDGFERSMN1; SMN2
SCHEMBL12226858 0.71 ALDH1A1 (0.38) RAB9ABRD4KCNH2GFERSMN1; SMN2
SCHEMBL12226852 0.70 NPC1 (0.54) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL12226857 0.70 ALDH1A1 (0.47) NPC1RAB9ABRD4KCNH2GFER
SCHEMBL2535885 0.68 PDE2A (0.39) SCDKDM4EMAPTALDH1A1GAA
SCHEMBL12226860 0.68 CA12 (0.46) NPC1RAB9ABRD4SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 — — US disclosed
EP-1697343-B1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2009-07-01 — — EP disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 NPC1 3348/4885RAB9A 912/4885EGFR 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback